甲基(4-亚硝基苯基)氨基甲酸酯 | 222400-05-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 甲基(4-亚硝基苯基)氨基甲酸酯
• 中文别名: (5-甲氧基-1H-吲哚-2-基)(吗啉-4-基)甲酮
• 英文名称: methyl N-(p-nitrosophenyl)carbamate
• 英文别名: methyl N-(4-nitrosophenyl)carbamate
• CAS: 222400-05-7
• 化学式: C₈H₈N₂O₃
• 分子量: 180.163
• InChiKey: BYLKXPPCVBXKFE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  67.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  甲基(4-亚硝基苯基)氨基甲酸酯 在 硝酸 作用下， 反应 1.0h， 以79%的产率得到甲基(4-硝基苯基)氨基甲酸酯
  参考文献：
  名称：

  Velikorodov, Russian Journal of Organic Chemistry, 2000, vol. 36, # 2, p. 233 - 239

  摘要：

  DOI：
• 作为产物：
  描述：

  N-苯基香豆甲酯 在 HSO₃ONO 作用下， 以 溶剂黄146 为溶剂， 反应 0.5h， 以65%的产率得到甲基(4-亚硝基苯基)氨基甲酸酯
  参考文献：
  名称：

  Velikorodov, Russian Journal of Organic Chemistry, 2000, vol. 36, # 2, p. 233 - 239

  摘要：

  DOI：

文献信息

• Derivatives Of Pentose Monosaccharides As Anti-Inflammatory Compounds
  申请人：Sattigeri Viswajanani Jitendra

  公开号：US20090075909A1

  公开（公告）日：2009-03-19

  The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds of this invention can be useful for inhibition and prevention of inflammation and associated pathologies, including inflammatory and autoimmune diseases, for example, bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection or psoriasis. The present invention also relates to pharmacological compositions containing these monosaccharide derivatives, as well as methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, and other inflammatory and/or auto immune disorders.

  本发明涉及单糖衍生物作为抗炎药剂。本发明的化合物可用于抑制和预防炎症及相关病理，包括炎症性和自身免疫性疾病，例如支气管哮喘、类风湿关节炎、I 型糖尿病、多发性硬化症、移植排斥或牛皮癣。本发明还涉及含有这些单糖衍生物的药物组合物，以及治疗支气管哮喘、慢性阻塞性肺病、类风湿关节炎、多发性硬化症、I 型糖尿病、牛皮癣、移植排斥和其他炎症和/或自身免疫性疾病的方法。
• Synthesis and Antimicrobial Action of Ninhydrin, Isatin, and 5-Acetyl-4-Hydroxy-1,3-Thiazine-2,6-Dione Derivatives Against Staphylococcus aureus and Pseudomonas aeruginosa Opportunistic Microflora
  作者：A. S. Zukhairaeva、A. V. Velikorodov、L. V. Saroyants、M. Yu. Yushin、A. V. Lutsenko、E. A. Shustova

  DOI：10.1007/s11094-022-02682-3

  日期：2022.8

  Series of new derivatives of ninhydrin, isatin, and 4-hydroxy-1,3-thiazine-2,6-dione were synthesized. Their antimicrobial activity against opportunistic microflora of Staphylococcus aureus and Pseudomonas aeruginosa isolated from neurotrophic ulcers of leprosy patients was studied. Antibacterial activity against S. aureus was observed for derivatives of chalcone (MIC 2.31 ± 0.99 and 8.0 ± 2.83 μg/mL), benzofuran (MIC 3.5 ± 1.66 μg/mL), imines (MIC 0.56 ± 0.16 and 3.01 ± 1.68 μg/mL), and indene (MIC 1.38 ± 0.38 μg/mL). Derivatives of imine (MIC 0.25 ± 0.05 and 0.63 ± 0.26 μg/mL) and indene also exhibited pronounced inhibitory effects against P. aeruginosa. Bactericidal effects on both cultures were observed for 5-(1E)-1-[2-(1-benzothiophen-2-yl)hydrazinylidene]-ethyl}-4-hydroxy-2H-1,3-thiazine-2,6(3H)-dione. An indene derivative with a morpholine fragment showed a pronounced bactericidal effect (MBC 2.3 ± 0.58 μg/mL) on the growth of P. aeruginosa culture.

  研究人员合成了一系列茚三酮、靛红和 4-羟基-1,3-噻嗪-2,6-二酮的新衍生物。研究了它们对从麻风病人神经营养性溃疡中分离出来的金黄色葡萄球菌和绿脓杆菌等机会性微生物的抗菌活性。发现查尔酮衍生物（MIC 2.31 ± 0.99 和 8.0 ± 2.83 μg/mL）、苯并呋喃衍生物（MIC 3.5 ± 1.66 μg/mL）、亚胺衍生物（MIC 0.56 ± 0.16 和 3.01 ± 1.68 μg/mL）和茚衍生物（MIC 1.38 ± 0.38 μg/mL）对金黄色葡萄球菌具有抗菌活性。亚胺的衍生物（MIC 0.25 ± 0.05 和 0.63 ± 0.26 μg/mL）和茚对铜绿假单胞菌也有明显的抑制作用。5-(1E)-1-[2-(1-benzothiophen-2-yl)hydrazinylidene]-ethyl}-4-hydroxy-2H-1,3-thiazine-2,6(3H)-dione 对两种培养物都有杀菌作用。带有吗啉片段的茚衍生物对铜绿假单胞菌的生长有明显的杀菌作用（MBC 2.3 ± 0.58 μg/mL）。
• Velikorodov, Russian Journal of Organic Chemistry, 2000, vol. 36, # 8, p. 1207 - 1209
  作者：Velikorodov

  DOI：——

  日期：——
• MONOSACCHARIDE DERIVATIVES
  申请人：Sattigeri Viswajanani Jitendra

  公开号：US20090221515A1

  公开（公告）日：2009-09-03

  The present invention relates to monosaccharide derivatives as anti-inflammatory agents. The compounds disclosed herein can be useful for inhibition and prevention of inflammation and associated pathologies, including inflammatory and autoimmune diseases such as bronchial asthma, rheumatoid arthritis, type I diabetes, multiple sclerosis, allograft rejection, psoriasis, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis or allergic rhinitis. Pharmacological compositions containing the compounds of the present invention and the methods of treating bronchial asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, multiple sclerosis, type I diabetes, psoriasis, allograft rejection, inflammatory bowel disease, ulcerative colitis, acne, atherosclerosis, cancer, pruritis, allergic rhinitis and other inflammatory and/or autoimmune disorders, using the compounds are also provided.